Skip to main content
. 2019 Sep 23;63(10):e00955-19. doi: 10.1128/AAC.00955-19

TABLE 1.

MICs of the KPC-producing strains

Antimicrobial agent MIC (μg/ml) in:
Patient B for:
Patient H for:
K. pneumoniae 01140-2 (KPC-31, ST258) E. hormaechei 04408-5 (KPC-40, ST407) K. pneumoniae 04409-2 (KPC-31, ST258) E. hormaechei 04409-1 (KPC-40, ST407)
Ceftazidime-avibactama 64 16 4 8
Ertapenem >4 4 >4 2
Imipenem >8 ≤1 >8 ≤1
Meropenem >8 ≤1 >8 ≤1
Cefotaxime >32 >32 >32 >32
Ceftazidime >16 >16 >16 >16
Cefepime >16 8 >16 8
Aztreonam >16 >16 >16 >16
Piperacillin-tazobactam >64/4 >64/4 >64/4 >64/4
Ciprofloxacin >2 ≤0.25 >2 ≤0.25
Levofloxacin >8 ≤1 >8 ≤1
Gentamicin ≤1 ≤1 ≤1 ≤1
Amikacin 16 ≤4 16 ≤4
Tobramycin >8 ≤1 >8 ≤1
Doxycycline >16 16 >16 16
Tigecycline 1 2 1 2
Colistin ≤0.25 ≤0.25 ≤0.25 ≤0.25
a

The breakpoint for ceftazidime-avibactam approved by the Clinical and Laboratory Standards Institute is ≤8/4 μg/ml for susceptible and ≥16/4 μg/ml for resistance.